UNAUDITED)
2007 2006
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income $ 5,382,096 $ 3,073,002
Adjustments to reconcile
net income to cash
provided by operating
activities:
Depreciation 1,187,166 802,766
Amortization 23,820 21,159
Allowance for bad debts (126,334) 718
Gain on equipment
disposal (90,098) --
Loss on disposal of
land use right 5,954 --
Earnings on equity
investment (149,757) (22,207)
Change in operating
assets and liabilities:
Accounts receivable (185,355) (1,042,970)
Notes receivable (772,571) (569,932)
Other receivables 1,186,223 (975)
Other receivables -
related party 2,531,257 (502,261)
Other receivables -
shareholder 1,254,248 --
Inventories 159,692 (393,469)
Prepayments (472,365) (139,392)
Prepayments - related
party -- (39,024)
Accounts payable (1,668,080) 896,568
Accounts payable -
related party (293,176) (412,070)
Accrued liabilities (150,906) 43,689
Other payable
'/>"/>
SOURCE Shengtai Pharmaceutical, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1.
Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results2.
Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 20083.
Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference4.
Shengtai Pharmaceutical, Inc. to Present at Roth Conference5.
Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger6.
BD to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference7.
Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference8.
Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City9.
MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference10.
Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference11.
Cardinal Health CEO of Clinical & Medical Products to Speak at Merrill Lynchs Global Pharmaceutical, Biotechnology and Medical Device Conference